Latest Ratios: P/E Ratio -1.8x · EV/EBITDA N/A · ROE -21.8%. (2007–2026 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $165M | $185M | $245M | $225M | $225M | $284M | $1.5B | $1.2B | $7.5B | $3.3B | $466M |
| Enterprise Value | $103M | $97M | $164M | $145M | $150M | $209M | $1.5B | $1.6B | $7.9B | $3.4B | $370M |
| P/E Ratio → | -1.76 | — | 154.04 | — | — | — | — | — | — | 47.13 | — |
| P/S Ratio | 0.73 | 0.58 | 0.71 | 0.83 | 1.01 | 1.28 | 6.23 | 4.47 | 30.62 | 60.37 | 25.78 |
| P/B Ratio | 0.42 | 0.36 | 0.40 | 0.37 | 0.43 | 0.54 | 0.75 | 0.57 | 1.71 | 2.13 | 2.12 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | 15.29 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.30 | 0.48 | 0.54 | 0.67 | 0.95 | 6.07 | 5.84 | 32.36 | 62.43 | 20.45 |
| EV / EBITDA | — | — | 5.98 | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | 5.71 | — | — | — | — | — | — | 38.68 | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 5.2% | 5.2% | 54.6% | 48.6% | 6.6% | 9.6% | -8.8% | -7.4% | 58.0% | 78.8% | 88.9% |
| Operating Margin | -50.8% | -50.8% | 1.4% | -17.2% | -92.6% | -104.6% | -115.3% | -173.3% | -129.6% | -173.5% | -61.9% |
| Net Profit Margin | -38.0% | -38.0% | 0.5% | -25.6% | -364.9% | -776.0% | -282.8% | -1221.7% | -119.5% | 130.3% | -71.8% |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -21.8% | -21.8% | 0.3% | -12.3% | -156.5% | -134.4% | -33.4% | -100.7% | -9.8% | 8.1% | -11.5% |
| ROA | -16.8% | -16.8% | 0.2% | -7.8% | -88.2% | -94.2% | -24.6% | -76.7% | -7.8% | 6.5% | -7.6% |
| ROIC | -25.8% | -25.8% | 0.7% | -7.2% | -34.7% | -14.2% | -9.5% | -9.6% | -7.3% | -8.0% | -12.0% |
| ROCE | -25.6% | -25.6% | 0.7% | -6.6% | -30.1% | -14.1% | -10.8% | -11.9% | -9.1% | -9.0% | -7.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.17 | 0.17 | 0.43 | 0.43 | 0.20 | 0.25 | 0.15 | 0.13 | 0.29 |
| Debt / EBITDA | — | — | 3.78 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.17 | -0.13 | -0.13 | -0.14 | -0.14 | -0.02 | 0.17 | 0.10 | 0.07 | -0.44 |
| Net Debt / EBITDA | — | — | -2.92 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -89.99 | -89.99 | 3.42 | -3.20 | -4.75 | -22.95 | -9.53 | -42.88 | -7.39 | 7.57 | -12.36 |
Net cash position: cash ($113M) exceeds total debt ($24M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.94 | 5.94 | 4.31 | 3.42 | 2.02 | 2.02 | 5.72 | 1.53 | 1.51 | 2.92 | 8.25 |
| Quick Ratio | 3.32 | 3.32 | 2.16 | 1.93 | 1.48 | 1.48 | 4.54 | 0.97 | 1.14 | 2.35 | 7.75 |
| Cash Ratio | 2.46 | 2.46 | 1.68 | 1.47 | 1.27 | 1.27 | 3.82 | 0.62 | 0.83 | 1.99 | 7.44 |
| Asset Turnover | — | 0.53 | 0.40 | 0.32 | 0.24 | 0.24 | 0.09 | 0.09 | 0.04 | 0.03 | 0.06 |
| Inventory Turnover | 1.74 | 1.74 | 0.65 | 0.74 | 1.62 | 1.55 | 1.94 | 1.88 | 0.63 | 0.27 | 0.17 |
| Days Sales Outstanding | — | 50.75 | 44.90 | 61.43 | 67.43 | 68.18 | 83.63 | 73.19 | 167.62 | 100.51 | 46.87 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 0.6% | — | — | — | — | — | — | 2.1% | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $57M | $56M | $51M | $32M | $21M | $17M | $10M | $8M | $4M | $2M |
Persistent Revenue Contraction Risk
According to recent market data, Aurora Cannabis trades at a price-to-sales ratio of 0.77, which, when compared to historical averages and peer valuations, suggests that investors are pricing in a high probability of continued dilution rather than a recovery in core operational profitability.
The negative P/E ratio and lack of a forward EV/EBITDA multiple indicate that the market currently views the company as a distressed asset rather than a growth-oriented entity. This valuation profile implies that the market is heavily discounting the company's intellectual property and international medical footprint due to the persistent history of shareholder dilution.
Based on reported financial figures, the company's ROIC has fluctuated between -3.6% and 5.4% over the last ten quarters, indicating that Aurora Cannabis has struggled to generate returns that exceed its cost of capital, largely due to the persistent drag of underutilized production assets.
The volatility in ROIC suggests that the company's attempts to pivot toward higher-margin medical segments have been offset by the high fixed-cost burden of its remaining infrastructure. Investors should monitor whether the recent rationalization of the facility footprint can finally stabilize these returns above the company's weighted average cost of capital.
As reported in quarterly filings, the cash conversion cycle has reached an elevated 753 days in 2026Q4, a significant deterioration that highlights the company's ongoing struggle to manage inventory levels effectively compared to more efficient peers in the specialty pharmaceutical and cannabis sectors.
The extremely high days inventory outstanding (DIO) of 917 days suggests that the company is carrying significant quantities of slow-moving or potentially obsolete product. This inefficiency in working capital management directly pressures liquidity and necessitates the frequent inventory write-downs that have historically plagued the company's gross margins.
According to the latest balance sheet data, the current ratio of 5.94 appears superficially strong, yet this figure is heavily skewed by the presence of inventory that may be difficult to liquidate, warranting a closer look at the quick ratio of 3.32.
While the liquidity position appears adequate on the surface, the reliance on inventory to meet short-term obligations is a significant risk factor. If the company cannot convert its medical and adult-use inventory into cash at expected price points, the actual liquidity available to fund operations may be significantly lower than the headline ratios suggest.
The most commonly misapplied metric for Aurora Cannabis is the price-to-sales ratio, which obscures the company's underlying lack of profitability and the high cost of goods sold associated with its specific, capital-intensive medical and propagation business model.
Investors often use P/S to compare ACB against broader consumer peers, but this ignores the fact that a significant portion of revenue is derived from low-margin wholesale channels. A more appropriate metric would be EV/Gross Profit, which better captures the company's ability to retain value after accounting for the high fixed costs of its production facilities.
Includes 30+ ratios · 20 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ACB stock.
Aurora Cannabis Inc.'s current P/E ratio is -1.8x. The historical average is 100.6x.
Aurora Cannabis Inc.'s return on equity (ROE) is -21.8%. The historical average is -55.4%.
Based on historical data, Aurora Cannabis Inc. is trading at a P/E of -1.8x. Compare with industry peers and growth rates for a complete picture.
Aurora Cannabis Inc. has 5.2% gross margin and -50.8% operating margin.